ACE INHIBITORS AND PROCAINAMIDE
The combination of captopril (or other ACE inhibitors) and procainamide possibly increases the risk of leucopenia, especially in patients with renal impairment. No pharmacokinetic interaction occurs between captopril and procainamide.
It is recommended that white cell counts are monitored before concurrent use, every 2 weeks during the first 3 months of combined treatment, and then periodically thereafter.
It is recommended that white cell counts are monitored before concurrent use, every 2 weeks during the first 3 months of combined treatment, and then periodically thereafter.